logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hyun Ae Jung

sung kyun kwan university
H指数:30
被引数:4,592

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study

拉泽替尼联合培美曲塞治疗表皮生长因子受体突变阳性非小细胞肺癌合并软脑膜转移的II期研究：KCSG LU 21-01、LAZARUS研究

Lung Cancer
IF4.4
2025-11-010
PRE
Hyun-Ae Jung; Tae Min Kim; Hye Ryun Kim; Chang Gon Kim; Hee Kyung Ahn; Youngjoo Lee; Yu Jung Kim; Miso Kim; Jeonghwan Youk; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Dong-Wan Kim; Myung-Ju Ahn; Bhumsuk Keam
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study

非小细胞肺癌中除EGFR、ALK和ROS1突变外具有可操作基因改变的患者，采用化疗联合免疫检查点抑制剂的联合治疗：一项回顾性观察性研究

BMC Cancer
IF3.4
2025-10-230
OAAI
Ji Eun Shin; Sehhoon Park; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Myung-Ju Ahn
Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab

前瞻性研究使用纵向游离细胞NGS探讨表皮生长因子受体20号外显子插入突变的非小细胞肺癌接受阿曼曲单抗治疗后的生物标志物和耐药机制

European Journal of Cancer
IF7.1
2025-07-100
PRE
Geun-Ho Park; Sehhoon Park; Hyemin Kim; Hyun-Ae Jung; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Se-Hoon Lee
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial

辅助培美曲塞疗法用于完全切除的Ⅰ期肺腺癌（伴微乳头或实性组织学亚型）的研究：一项单中心、单臂、II期临床试验

eClinicalMedicine
IF10
2025-06-040
OA
Jhingook Kim; Yeong Hak Bang; Sehhoon Park; Hyun-Ae Jung; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Yeong Jeong Jeon; Junghee Lee; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jae Ill Zo; Young Mog Shim; Jung Hee Kang; Jinseon Lee; Yoon-La Choi; Joungho Han; Soohyun Hwang; Ho Yun Lee; Se-Hoon Lee
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18

根据EGFR和ALK状态，不可切除的局部晚期III期NSCLC在确定性同步放化疗后维持Durvalumab的临床结局: 韩国癌症研究小组LU-22-18

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-12-010
OA
Choi, Dae-Ho; Kim, Miso; Kim, Young Saing; Park, Keon Uk; Cho, Jang Ho; Kim, Hongsik; Lee, Ki Hyeong; Ahn, Heejoon; Kim, Il-Hwan; Lee, Kyung-Hee; Lee, Gyeong-Won; Yi, Seong Yoon; Ahn, Beung chul; Lee, Min-Young; Jung, Hyun Ae; Park, Sehhoon; Sun, Jong-Mu; Ahn, Jin Seok; Lee, Se-Hoon; Ahn, Myung-Ju
Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial

ATTLAS III期试验中接受阿替利珠单抗联合贝伐珠单抗和化疗治疗的EGFR突变NSCLC患者的探索性生物标志物分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Kim, H.; Park, S.; Kim, T. M.; Han, J-Y.; Lee, G-W.; Shim, B. Y.; Lee, Y-G.; Kim, S-W.; Ock, C-Y.; Hwang, S.; Lee, Y.; Kim, R.; Jung, H. A.; Sun, J-M.; Lee, S-H.; Ahn, J. S.; Ahn, M-J.

研究方向

暂未获取到该数据
S
Se‐Hoon Lee
H 指数:87论文数:1,134被引数:3.2万
J
Jin Seok Ahn
H 指数:71论文数:823被引数:2.2万
M
Myung‐Ju Ahn
H 指数:109论文数:1,300被引数:7.2万
K
Keunchil Park
H 指数:113论文数:958被引数:7.3万
J
Jong‐Mu Sun
H 指数:56论文数:387被引数:1.2万
S
Sehhoon Park
H 指数:22论文数:154被引数:1,891
J
Jong‐Mu Sun
H 指数:31论文数:130被引数:5,348
Y
Yoon‐La Choi
H 指数:71论文数:509被引数:2.0万
S
Sehhoon Park
H 指数:17论文数:166被引数:886
S
SH Lee
H 指数:34论文数:350被引数:3,633